FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease. Additionally, FSD Pharma is actively developing Lucid-PSYCH, a psychoactive molecule identified for its potential in addressing neuropsychiatric conditions such as depressive disorder. They are also advancing Lucid-MS, a proprietary new chemical entity which, in preclinical models, has demonstrated the capacity to prevent and reverse myelin degradation—the fundamental mechanism behind multiple sclerosis. Established in 1998, FSD Pharma Inc. is headquartered in Toronto, Canada.